血球貪食性リンパ組織球症治療薬の世界市場:疫学予測

◆英語タイトル:Hemophagocytic Lymphohistiocytosis Epidemiology Forecast to 2030
◆商品コード:DELV20JU202
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:90
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(202名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Hemophagocytic Lymphohistiocytosis- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophagocytic Lymphohistiocytosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
Hemophagocytic Lymphohistiocytosis Understanding
The DelveInsight Hemophagocytic Lymphohistiocytosis epidemiology report gives a thorough understanding of the Hemophagocytic Lymphohistiocytosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hemophagocytic Lymphohistiocytosis in the US, Europe, and Japan. The report covers the detailed information of the Hemophagocytic Lymphohistiocytosis epidemiology scenario in seven major countries (US, EU5, and Japan).

Hemophagocytic Lymphohistiocytosis Epidemiology Perspective by DelveInsight
The Hemophagocytic Lymphohistiocytosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Hemophagocytic Lymphohistiocytosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Hemophagocytic Lymphohistiocytosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hemophagocytic Lymphohistiocytosis Detailed Epidemiology Segmentation
The Hemophagocytic Lymphohistiocytosis epidemiology covered in the report provides historical as well as forecasted Hemophagocytic Lymphohistiocytosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Hemophagocytic Lymphohistiocytosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
The Hemophagocytic Lymphohistiocytosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Hemophagocytic Lymphohistiocytosis Epidemiology Report and Model provide an overview of the global trends of Hemophagocytic Lymphohistiocytosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Hemophagocytic Lymphohistiocytosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Hemophagocytic Lymphohistiocytosis
The report provides the segmentation of the Hemophagocytic Lymphohistiocytosis epidemiology
Report Highlights
11-year Forecast of Hemophagocytic Lymphohistiocytosis epidemiology
7MM Coverage
Incident Cases of Hemophagocytic Lymphohistiocytosis
Familial Hemophagocytic Lymphohistiocytosis by Mutation Types
Secondary HLH Cases by Etiologies
KOL Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hemophagocytic Lymphohistiocytosis?

• What are the key findings pertaining to the Hemophagocytic Lymphohistiocytosis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?

• What would be the total number of patients of Hemophagocytic Lymphohistiocytosis across the 7MM during the forecast period (2017–2030)?

• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?

• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?

• What is the disease risk, burden and unmet needs of Hemophagocytic Lymphohistiocytosis?

• What are the currently available treatments of Hemophagocytic Lymphohistiocytosis?

Reasons to buy
The Hemophagocytic Lymphohistiocytosis Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Hemophagocytic Lymphohistiocytosis market
Quantify patient populations in the global Hemophagocytic Lymphohistiocytosis market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hemophagocytic Lymphohistiocytosis therapeutics in each of the markets covered
Understand the magnitude of Hemophagocytic Lymphohistiocytosis population by its epidemiology
The Hemophagocytic Lymphohistiocytosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Hemophagocytic Lymphohistiocytosis

3. SWOT Analysis for HLH

4. Disease Background and Overview

4.1. Introduction

4.2. History

4.3. Classification

4.4. Sub-types

4.5. Causes

4.6. Symptoms

4.7. Clinical Presentation

4.8. Pathophysiology

4.9. Diagnosis

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Assumptions and Rationale – 7MM

5.3. 7MM Total Incident Patient Population of Hemophagocytic Lymphohistiocytosis

6. Country Wise-Epidemiology of Hemophagocytic Lymphohistiocytosis

6.1. The United States

6.1.1. Total Incident Cases of Hemophagocytic Lymphohistiocytosis in the United States

6.1.2. Familial HLH cases by Mutation Types in the United States

6.1.3. Secondary HLH Cases by Etiologies in the United States

6.2. EU5

6.2.1. Germany

6.2.2. France

6.2.3. Italy

6.2.4. Spain

6.2.5. The United Kingdom

6.3. Japan

7. Treatment

7.1. Guidelines

7.2. HLH-2004: Diagnostic and Therapeutic Guidelines for HLH

7.3. Management of Hemophagocytic Lymphohistiocytosis

8. Unmet Needs

9. Organizations contributing toward Hemophagocytic Lymphohistiocytosis

10. KOL’s Views: Hemophagocytic Lymphohistiocytosis

11. Case Studies

11.1. Fever of Unknown Origin

11.2. A Challenging Diagnosis

12. Appendix

12.1. Report Methodology

12.2. Bibliography

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Table 1: Summary of Hemophagocytic Lymphohistiocytosis Market, Epidemiology, and Key Events (2017–2030)

Table 2: Histiocytoses of the H group: classification of HLH

Table 3: List of abnormalities associated with HLH

Table 4: Clinical Manifestations associated with HLH in Children and Adults

Table 5: Laboratory Presentations associated with HLH in Children and Adults

Table 6: HLH-2004 Diagnostic Criteria

Table 7: Historical Review of Nomenclature and Diagnostic Criteria in HLH

Table 8: The HScore

Table 9: Genetic Testing in HLH

Table 10: Incident Patient Population of Hemophagocytic Lymphohistiocytosis in 7MM (2017–2030)

Table 11: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in the United States (2017–2030)

Table 12: Hemophagocytic Lymphohistiocytosis cases by Mutation Types in the United States (2017–2030)

Table 13: Secondary HLH Cases by Etiologies in the United States (2017–2030)

Table 14: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Germany (2017–2030)

Table 15: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in Germany (2017–2030)

Table 16: Secondary HLH Cases by Etiologies in Germany (2017–2030)

Table 17: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in France (2017–2030)

Table 18: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in France (2017–2030)

Table 19: Secondary HLH Cases by Etiologies in France (2017–2030)

Table 20: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Italy (2017–2030)

Table 21: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in Italy (2017–2030)

Table 22: Secondary HLH Cases by Etiologies in Italy (2017–2030)

Table 23: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Spain (2017–2030)

Table 24: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in Spain (2017–2030)

Table 25: Secondary HLH Cases by Etiologies in Spain (2017–2030)

Table 26: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in the United Kingdom (2017–2030)

Table 27: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in the UK (2017–2030)

Table 28: Secondary HLH Cases by Etiologies in the UK (2017–2030)

Table 29: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Japan (2017–2030)

Table 30: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in Japan (2017–2030)

Table 31: Secondary HLH Cases by Etiologies in Japan (2017–2030)

Table 32: Organizations contributing toward HLH

List of Figures

Figure 1: SWOT Analysis

Figure 2: Pathogenesis of HLH

Figure 3: Normal Cytotoxic Function

Figure 4: Pathophysiology of Primary HLH

Figure 5: Pathophysiology of HLH due to Inborn Errors of Immunity

Figure 6: Mechanisms Through Which Viruses Contribute to HLH

Figure 7: Pathogenic Mechanisms contributing to HLH

Figure 8: Mechanisms that contribute to increased predisposition to MAS

Figure 9: A General Approach Towards the Diagnosis of HLH

Figure 10: Incident Patient Population of Hemophagocytic Lymphohistiocytosis in 7MM (2017–2030)

Figure 11: Total Incident Cases of HLH in the United States (2017–2030)

Figure 12: Familial HLH cases by Mutation Types in the United States (2017–2030)

Figure 13: Secondary HLH Cases by Etiologies in the United States (2017–2030)

Figure 14: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Germany (2017–2030)

Figure 15: Familial HLH cases by Mutation Types in Germany (2017–2030)

Figure 16: Secondary HLH Cases by Etiologies in Germany (2017–2030)

Figure 17: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in France (2017–2030)

Figure 18: Familial HLH cases by Mutation Types in France (2017–2030)

Figure 19: Secondary HLH Cases by Etiologies in France (2017–2030)

Figure 20: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Italy (2017–2030)

Figure 21: Familial Hemophagocytic Lymphohistiocytosis cases by Mutation Types in Italy (2017–2030)

Figure 22: Secondary HLH Cases by Etiologies in Italy (2017–2030)

Figure 23: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Spain (2017–2030)

Figure 24: Familial HLH cases by Mutation Types in Spain (2017–2030)

Figure 25: Secondary HLH Cases by Etiologies in Spain (2017–2030)

Figure 26: Total Incident Cases of HLH in the United Kingdom (2017–2030)

Figure 27: Familial HLH cases by Mutation Types in the UK (2017–2030)

Figure 28: Secondary HLH Cases by Etiologies in the UK (2017–2030)

Figure 29: Total Incident Cases of Hemophagocytic Lymphohistiocytosis in Japan (2017–2030)

Figure 30: Familial HLH cases by Mutation Types in Japan (2017–2030)

Figure 31: Secondary HLH Cases by Etiologies in Japan (2017–2030)

Figure 32: Treatment Algorithm of HLH in Adults

Figure 33: Treatment Algorithm of HLH in Adults

Figure 34: Treatment Algorithm of HLH in Adults including MAS-HLH

Figure 35: Algorithm for treating HLH among Children

Figure 36: HLH-2004: Schematic Treatment Overview

Figure 37: Unmet Needs of Hemophagocytic Lymphohistiocytosis

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血球貪食性リンパ組織球症治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆